Ascendis Pharma Secures FDA Approval for YORVIPATH, a Novel Hormone Replacement Therapy for Hypoparathyroidism

FDA Approval:
The U.S. Food and Drug Administration (FDA) has approved YORVIPATH (palopegteriparatide) for the treatment of hypoparathyroidism, a rare hormone deficiency disorder.

First and Only:
YORVIPATH is the first and only FDA-approved drug for this condition, marking a significant milestone for Ascendis Pharma.

Development:
The drug was developed as TransCon PTH, a peptide therapy designed to address deficient levels of parathyroid hormone in patients with hypoparathyroidism.

Launch Preparation:
Ascendis Pharma is well-prepared for the U.S. launch of YORVIPATH, following the hard-fought FDA approval.

Significance:
This approval is a significant achievement for Ascendis Pharma, as it addresses a previously unmet medical need for patients with hypoparathyroidism.